Drug intelligence / Profile preview

H-1129

Development stage: Preclinical
Lead developer: D. Western Therapeutics Institute
Modality: Small Molecules
Administration: Ophthalmic

Overview

H-1129 is a small molecule drug candidate developed by D. Western Therapeutics Institute (DWTI) for the treatment of keratoconjunctival diseases associated with immune disorders. The compound is currently in the preclinical stage, with the company preparing for clinical trial applications (Pre-IND) in Japan. While the specific molecular target and mechanism of action have not been publicly disclosed, the drug is being developed internally by DWTI, a company that specializes in the discovery of protein kinase inhibitors for ophthalmic and other conditions using its proprietary drug discovery platforms.

Targets

HSP90AA1 (Heat shock protein HSP90-alpha)ROCK1 (Rho-associated coiled-coil containing protein kinase 1)

Beyond the preview

Go deeper on H-1129.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on H-1129.

Explore the full profile